II. Indications
-
Multiple Sclerosis (relapsing)
- Typically in combination with other MS agents (e.g. Interferon Beta, glatiramir)
III. Mechanism
- Immunomodulatory agent that inhibits Pyrimidine synthesis
- Teriflunomide is an active metabolite of Leflunomide
IV. Medications
- Teriflunomide (Aubagio) tablets: 7 mg, 14 mg
V. Dosing
- Adults: 7 to 14 mg orally once daily
VI. Adverse Effects
- Hepatotoxicity (black-box warning)
- May be severe or fatal, similar to Leflunomide toxicity (uncommon)
- Stop Teriflunomide at the first sign of liver toxicity
- Gastrointestinal
- Neurologic
- Dermatologic
VII. Safety
- Unknown safety in Lactation
- Contraindicated in Pregnancy
- Pregnancy Category X in all trimesters
- Use effective Contraception
- Men and women should not try to conceive until Teriflunomide serum levels are <0.02 mcg/ml
- Monitoring
- Liver Function Tests (at baseline and then every 6 months)
- Complete Blood Count (at baseline and periodically, including with signs infection)
VIII. Resources
Images: Related links to external sites (from Bing)
Related Studies
teriflunomide (on 9/20/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
TERIFLUNOMIDE 14 MG TABLET | Generic | $0.91 each |
Ontology: teriflunomide (C1718383)
Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
MSH | C527525 |
SnomedCT | 703786007, 703785006 |
LNC | LP36784-4, MTHU020205 |
English | teriflunomide, (Z)-2-Cyano-alpha'alpha'alpha-trifluoro-3-hydroxy-p-crotonotoluidide, N-(4-Trifluoromethylphenyl)-2-cyano-2-hydroxycrotonamide, TERIFLUNOMIDE, teriflunomide (medication), immunomodulators teriflunomide, Teriflunomide (product), Teriflunomide, Teriflunomide (substance) |